All News
Filter News
Found 463 articles
-
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
9/29/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of treatment with verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS).
-
Biohaven Announces Record Date for Anticipated Spin-Off
9/19/2022
Biohaven Pharmaceutical Holding Company Ltd. announced that it has set a record date of September 26, 2022 for the previously announced spin-off by Biohaven of its Biohaven Ltd. subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven.
-
Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
8/31/2022
Biohaven Pharmaceutical Holding Company Ltd. announced the important findings pertaining to the benefit of Nurtec® ODT in decreasing the burden of butalbital use among migraine patients in real world clinical practice.
-
Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
8/23/2022
Freedom Biosciences today emerged from stealth with $10.5 million in seed financing.
-
Lundbeck revealed that its migraine drug Vyepti failed to demonstrate statistical superiority over placebo at reducing the number of monthly migraine days.
-
Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
8/19/2022
Akili, a leading digital medicine company, completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I, a publicly traded special purpose acquisition company.
-
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
8/5/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the second quarter ended June 30, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.
-
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
8/1/2022
Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.
-
COVID-19 has been remarkably profitable for Pfizer over the last year-and-a-half. The company’s revenue jumped by 47% to $27.7 billion compared to the same period in 2021.
-
Pfizer Reports Second-Quarter 2022 Results
7/28/2022
Pfizer Inc. reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance.
-
Migraine Drugs Market Is Expected to Witness Rapid Growth in Coming Years
7/26/2022
Migraine treatments are intended to stop the symptoms or for preventing future attacks on the patients.
-
Obsessive Compulsive Disorder Market Will Reflect the Noticeable CAGR by the end of Forecast Period 2030
7/26/2022
Forecast to 2030,’ thoroughly examines the Obsessive Compulsive Disorder industry to provide essential data & information for the targeted readers.
-
Ataxia Treatment Market: Strategic Analysis to Understand Competitive Outlook for the Industry till 2030
7/25/2022
Forecast to 2030,’ thoroughly examines the Ataxia Treatment industry to provide essential data & information for the targeted readers.
-
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
7/21/2022
Sosei Group Corporation (“the Company”; TSE: 4565), today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial.
-
Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics
7/21/2022
Artizan Biosciences, Inc. today announced that it has entered into a multi-year research collaboration with the University Medical Center Utrecht (“UMC Utrecht”) in The Netherlands and Microviable Therapeutics.
-
Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.
-
Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding
7/12/2022
Areteia will initiate Phase 3 trials of lead candidate, dexpramipexole, a potential first-in-class oral drug for eosinophilic asthma, in late 2022.
-
PureTech Founded Entity Akili Announces Public Company Board of Director Nominees
7/11/2022
New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS.
-
Merck is in late-stage discussions to acquire Seagen for about $40 billion according to a Wall Street Journal report.
-
Intercept Pharmaceuticals, Annovis Bio and Biohaven Pharma are moving forward with late-stage Phase III clinical trials.